Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients

被引:65
作者
Partida-Hernandez, G. [1 ]
Arreola, F.
Fenton, B.
Cabeza, M.
Roman-Ramos, R.
Revilla-Monsalve, M. C.
机构
[1] UMSNH, Fac Med & Biol Sci Doctor Ignacio Chavez, Clin & Expt Diabet Mellitus Lab, Morelia, Michoacan, Mexico
[2] Univ Autonoma Metropolitana, Biol Sci Doctorate Program, Mexico City, DF, Mexico
[3] CEYAMED, Diabet Educ & Med Attent Ctr, Morelia, Michoacan, Mexico
[4] UMSNH, Fac Med & Biol Sci Doctor Ignacio Chavez, Glycobiol Lab, Morelia, Michoacan, Mexico
[5] Metropolitan Univ Xochimilco, Dept Biol Syst, Mexico City, DF, Mexico
[6] Univ Autonoma Metropolitana Iztapalapa, Div Biol & Hlth Sci, Mexico City 09340, DF, Mexico
[7] Mexico Inst Social Secur, Natl Med Ctr Siglo 21, Med Res Unit Metab Dis, Mexico City, DF, Mexico
关键词
diabetes mellitus; zinc replacement; lipids;
D O I
10.1016/j.biopha.2006.02.004
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Abnormal zinc and lipid plasma levels occur more frequently in metabolically uncontrolled diabetic patients. These lipid alterations are key factors in the emergence of microvascular complications, which lead to death in those patients. Yet, zinc sulfate supplementation may be a therapeutical resource to recover some functioning and improve life span. This article reports the assessment of lipid profile from type 2-diabetes mellitus patients treated with hypoglycemic therapy drugs, who additionally presented zinc levels lower than average in Mexican reference. The patients received a 100 mg zinc sulfate treatment in a crossover double-blind design of clinically controlled study with starch as placebo. The diabetic patients had changes in their lipid profile after a 12-week zinc treatment as compared with placebo treatment. The 100 mg zinc sulfate treatment was well tolerated, significantly reduced total cholesterol and triglyceride concentrations, and increased those corresponding to zinc as well as HDL cholesterol in the bloodstream. Thus, using this treatment the cardiovascular involvement is expected to decrease in the type 2-diabetes mellitus patients, especially those with myocardial infarction and stroke, which are the main death causes in Mexico. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 66 条
[1]  
ABDELMAGEED AB, 1990, VET HUM TOXICOL, P32
[2]   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[3]  
*AM DIAB ASS, 1998, THER DIAB MELL REL D
[4]  
*AM DIAB ASS, 1992, OPHTHALMOLOGY, V99, P1626
[5]  
*AM MED ASS, 1997, ARCH INTERN MED, V157, P2423
[6]  
AMADOR ROL, 2005, REV MED IMSS, V43, P199
[7]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[8]   World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects [J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20) :2191-2194
[9]   EFFECT OF ZINC TREATMENT ON SERUM THYROID-HORMONES IN UREMIC PATIENTS UNDER PERITONEAL-DIALYSIS [J].
ARREOLA, F ;
PANIAGUA, R ;
PEREZ, A ;
DIAZBENSUSSEN, S ;
JUNCO, E ;
VILLALPANDO, S ;
EXAIRE, E .
HORMONE AND METABOLIC RESEARCH, 1993, 25 (10) :539-542
[10]  
ARREOLA F, 1990, ARCH INVEST MED, V21, P195